Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

BACKGROUND: Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma patients. METHODS: We conducted a phase I/II study of the EGFR inhibitor erlotinib (150 mg/day) and the mTOR inhibitor temsirol...

Full description

Saved in:
Bibliographic Details
Main Authors: Wen, Patrick Y., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Norden, Andrew D., Cloughesy, Timothy F., Robins, H. Ian, Lieberman, Frank S., Gilbert, Mark R., Mehta, Minesh P., Drappatz, Jan, Groves, Morris D., Santagata, Sandro, Ligon, Azra H., Yung, W.K. Alfred, Wright, John J., Dancey, Janet, Aldape, Kenneth D., Prados, Michael D., Ligon, Keith L.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2014
Subjects:
Clinical Investigations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3956354/
https://ncbi.nlm.nih.gov/pubmed/24470557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not247
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items